<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pepgen Ltd — News on 6ix</title>
    <link>https://6ix.com/company/pepgen-ltd</link>
    <description>Latest news and press releases for Pepgen Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/pepgen-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ab1578dffbe2df10d708.webp</url>
      <title>Pepgen Ltd</title>
      <link>https://6ix.com/company/pepgen-ltd</link>
    </image>
    <item>
      <title>PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-announces-topline-results-from-lowest-dose-5-mgkg-mad-cohort-in-the-ongoing-phase-2-freedom2-study-demonstrating-favorable-safety-splicing-and-vhot-data</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-announces-topline-results-from-lowest-dose-5-mgkg-mad-cohort-in-the-ongoing-phase-2-freedom2-study-demonstrating-favorable-safety-splicing-and-vhot-data</guid>
      <pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
      <description>– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of</description>
    </item>
    <item>
      <title>PepGen Announces Regulatory Updates on FREEDOM2</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-announces-regulatory-updates-on-freedom2-109</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-announces-regulatory-updates-on-freedom2-109</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate</description>
    </item>
    <item>
      <title>PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-reports-fourth-quarter-and-year-end-2025-financial-results-and-recent-corporate-highlights-136</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-reports-fourth-quarter-and-year-end-2025-financial-results-and-recent-corporate-highlights-136</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>– FREEDOM2-DM1 5 mg/kg cohort data expected in Q1 2026 – – Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data</description>
    </item>
    <item>
      <title>PepGen to Participate in the Leerink Global Healthcare Conference</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-to-participate-in-the-leerink-global-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-to-participate-in-the-leerink-global-healthcare-conference</guid>
      <pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
      <description>BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with</description>
    </item>
    <item>
      <title>PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-reports-inducement-grant-under-120000621</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-reports-inducement-grant-under-120000621</guid>
      <pubDate>Tue, 09 Dec 2025 12:00:00 GMT</pubDate>
      <description>BOSTON, December 09, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its newly appointed Chief Business and Legal Officer, Joseph Vittiglio.</description>
    </item>
    <item>
      <title>PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-appoints-joseph-vittiglio-esq-120000538</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-appoints-joseph-vittiglio-esq-120000538</guid>
      <pubDate>Mon, 08 Dec 2025 12:00:00 GMT</pubDate>
      <description>BOSTON, December 08, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than two decades of executive leadership experience across legal, compliance, corporate development, and corporate governance with</description>
    </item>
    <item>
      <title>PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-announces-issuance-u-patent-120500347</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-announces-issuance-u-patent-120500347</guid>
      <pubDate>Wed, 12 Nov 2025 12:05:00 GMT</pubDate>
      <description>BOSTON, November 12, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new composition of matter patent covering PGN-EDODM1, which leverages PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform, including i</description>
    </item>
    <item>
      <title>PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-reports-third-quarter-2025-120000666</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-reports-third-quarter-2025-120000666</guid>
      <pubDate>Wed, 12 Nov 2025 12:00:00 GMT</pubDate>
      <description>BOSTON, November 12, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2025.</description>
    </item>
    <item>
      <title>PepGen to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-participate-upcoming-investor-conferences-120000054</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-participate-upcoming-investor-conferences-120000054</guid>
      <pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
      <description>BOSTON, November 03, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:</description>
    </item>
    <item>
      <title>PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-announces-oral-presentations-30th-110000049</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-announces-oral-presentations-30th-110000049</guid>
      <pubDate>Thu, 02 Oct 2025 11:00:00 GMT</pubDate>
      <description>BOSTON, October 02, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company’s data will be presented in two oral presentations at the 30th Annual International Congress of the World Muscle Society (WMS) being held October 7-12, 2025, in Vienna, Austria. One of the presentations will include prev</description>
    </item>
    <item>
      <title>PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-announces-closing-underwritten-public-200100114</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-announces-closing-underwritten-public-200100114</guid>
      <pubDate>Fri, 26 Sep 2025 20:01:00 GMT</pubDate>
      <description>BOSTON,, September 26, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the closing of its previously announced underwritten public offering of 35,937,500 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 4,687,500 additional shares, at the public off</description>
    </item>
    <item>
      <title>PepGen Announces Pricing of $100 Million Public Offering</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-announces-pricing-100-million-025100766</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-announces-pricing-100-million-025100766</guid>
      <pubDate>Thu, 25 Sep 2025 02:51:00 GMT</pubDate>
      <description>BOSTON, September 25, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 31,250,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to PepGen from this offering are expected to be $100 million, before deducting</description>
    </item>
    <item>
      <title>PepGen Announces Proposed Public Offering</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-announces-proposed-public-offering-202100596</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-announces-proposed-public-offering-202100596</guid>
      <pubDate>Wed, 24 Sep 2025 20:21:00 GMT</pubDate>
      <description>BOSTON, September 24, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants are bei</description>
    </item>
    <item>
      <title>PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-announces-highest-mean-splicing-201600208</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-announces-highest-mean-splicing-201600208</guid>
      <pubDate>Wed, 24 Sep 2025 20:16:00 GMT</pubDate>
      <description>BOSTON, September 24, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced positive clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study in patients with myotonic dystrophy type 1 (DM1). These latest results demonstrated a mean splicing correction o</description>
    </item>
    <item>
      <title>PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-reports-second-quarter-2025-120000689</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-reports-second-quarter-2025-120000689</guid>
      <pubDate>Thu, 07 Aug 2025 12:00:00 GMT</pubDate>
      <description>BOSTON, August 07, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025.</description>
    </item>
    <item>
      <title>PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-focus-development-promising-dm1-200500901</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-focus-development-promising-dm1-200500901</guid>
      <pubDate>Wed, 28 May 2025 20:05:00 GMT</pubDate>
      <description>BOSTON, May 28, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, today announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping, the Company will focus on advancing its promising myotonic dystrophy type 1 (DM1) program currently in Phase 2 clinical developm</description>
    </item>
    <item>
      <title>PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-appoints-kasra-kasraian-phd-110000111</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-appoints-kasra-kasraian-phd-110000111</guid>
      <pubDate>Tue, 20 May 2025 11:00:00 GMT</pubDate>
      <description>BOSTON, May 20, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as wel</description>
    </item>
    <item>
      <title>PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-reports-first-quarter-2025-120000360</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-reports-first-quarter-2025-120000360</guid>
      <pubDate>Thu, 08 May 2025 12:00:00 GMT</pubDate>
      <description>BOSTON, May 08, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025.</description>
    </item>
    <item>
      <title>PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-present-24th-annual-needham-200500322</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-present-24th-annual-needham-200500322</guid>
      <pubDate>Wed, 02 Apr 2025 20:05:00 GMT</pubDate>
      <description>BOSTON, April 02, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 1:30pm ET.</description>
    </item>
    <item>
      <title>PepGen Announces Appointment of Two New Directors to its Board</title>
      <link>https://6ix.com/company/pepgen-ltd/news/pepgen-announces-appointment-two-directors-200500705</link>
      <guid isPermaLink="true">https://6ix.com/company/pepgen-ltd/news/pepgen-announces-appointment-two-directors-200500705</guid>
      <pubDate>Mon, 31 Mar 2025 20:05:00 GMT</pubDate>
      <description>BOSTON, March 31, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company.</description>
    </item>
  </channel>
</rss>